Table 1.
Demographic and clinical descriptions of NSCLC patients in the discovery and validation phases
| Variable | Discovery phase (N = 604) | Validation phase (N = 839) |
|---|---|---|
| Age (years) | 66.02 ± 9.55 | 63.51 ± 9.34 |
| Gender, N (%) | ||
| Male | 355 (58.77%) | 411 (56.38%) |
| Female | 249 (41.23%) | 318 (43.62%) |
| Unknown | 0 | 110 |
| Race, N (%) | ||
| Asian | 8 (1.32%) | 0 |
| Black | 55 (9.11%) | 0 |
| White | 541 (89.57%) | 0 |
| Unknown | 0 | 839 |
| Smoke status, N (%) | ||
| Never | 0 | 26 (6%) |
| Former | 416 (68.87%) | 243 (56.12%) |
| Current | 188 (31.13%) | 164 (37.88%) |
| Unknown | 0 | 406 |
| Smoking packs every year | 47.38 ± 29.96 | – |
| Clinical stage, N (%) | ||
| I | 328 (54.30%) | 496 (68.04%) |
| II | 171 (28.31%) | 172 (23.59%) |
| III | 88 (14.57%) | 53 (7.27%) |
| IV | 17 (2.81%) | 8 (1.10%) |
| Unknown | 0 | 110 |
| Histology, N (%) | ||
| LUAD | 294 (48.68%) | 634 (75.57%) |
| LUSC | 310 (51.32%) | 205 (24.43%) |
| Survival year | ||
| Median (95% CI) | 3.91 (3.33–4.93) | 7.53 (6.30–8.92) |
| Censoring rate | 59.60% | 55.66% |